Edition:
United States

Albireo Pharma Inc (ALBO.OQ)

ALBO.OQ on NASDAQ Stock Exchange Capital Market

23.43USD
16 Aug 2019
Change (% chg)

$1.21 (+5.45%)
Prev Close
$22.22
Open
$22.36
Day's High
$24.03
Day's Low
$22.36
Volume
14,682
Avg. Vol
16,495
52-wk High
$38.48
52-wk Low
$19.43

Latest Key Developments (Source: Significant Developments)

Albireo Pharma Q2 Loss Per Share $1.35
Thursday, 8 Aug 2019 07:30am EDT 

Aug 8 (Reuters) - Albireo Pharma Inc ::ALBIREO REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS.Q2 LOSS PER SHARE $1.35.Q2 REVENUE $1.3 MILLION VERSUS $700,000.Q2 REVENUE ESTIMATE $767,000 -- REFINITIV IBES DATA.Q2 EARNINGS PER SHARE ESTIMATE $-1.43 -- REFINITIV IBES DATA.ODEVIXIBAT PHASE 3 PEDFIC 1 TOPLINE RESULTS EXPECTED MID-2020.COMPANY HAD CASH AND CASH EQUIVALENTS AT JUNE 30, 2019, OF $157.7 MILLION.ANTICIPATES ITS CURRENT CASH BALANCE TO BE SUFFICIENT TO MEET ITS OPERATING NEEDS INTO 2021.  Full Article

Albireo Provides Mid-Year Clinical Development Update
Tuesday, 9 Jul 2019 04:05pm EDT 

July 9 (Reuters) - Albireo Pharma Inc ::ALBIREO PROVIDES MID-YEAR CLINICAL DEVELOPMENT UPDATE.ALBIREO PHARMA INC - EXPECTS ODEVIXIBAT PEDFIC 1 PHASE 3 TOPLINE DATA MID-2020 -.ALBIREO PHARMA INC - SITE ACTIVATED FOR ODEVIXIBAT PEDFIC 2 EXPANDED OPEN-LABEL COHORT.ALBIREO PHARMA INC - ODEVIXIBAT BILIARY ATRESIA PIVOTAL TRIAL EXPECTED TO BEGIN IN 2020.ALBIREO PHARMA INC - MOVES INTO NASH WITH INITIATION OF ELOBIXIBAT PHASE 2 TRIAL.ALBIREO PHARMA INC - ENCOURAGED WITH RECRUITING EFFORTS BY PARTICIPATING SITES IN OUR PHASE 3 TRIAL FOR ODEVIXIBAT IN PFIC.  Full Article

Albireo Pharma Reports Q1 Loss Per Share Of $1.39
Thursday, 9 May 2019 07:30am EDT 

May 9 (Reuters) - Albireo Pharma Inc ::ALBIREO REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS.Q1 LOSS PER SHARE $1.39.Q1 REVENUE $570,000 VERSUS $11.2 MILLION.Q1 REVENUE ESTIMATE $974,000 -- REFINITIV IBES DATA.Q1 EARNINGS PER SHARE ESTIMATE $-1.32 -- REFINITIV IBES DATA.FOR FY 2019, ANTICIPATE TOTAL EXPENSES, INCLUDING RESEARCH AND DEVELOPMENT AND G&A EXPENSES, TO BE IN RANGE OF $75-$80 MILLION.ANTICIPATE CURRENT CASH BALANCE TO BE SUFFICIENT TO MEET OUR OPERATING NEEDS INTO 2021.  Full Article

Albireo Announces FDA Clearance of IND to Commence Phase 2 Trial of Elobixibat
Thursday, 11 Apr 2019 07:30am EDT 

April 11 (Reuters) - Albireo Pharma Inc ::ALBIREO ANNOUNCES FDA CLEARANCE OF IND TO COMMENCE PHASE 2 TRIAL OF ELOBIXIBAT FOR THE TREATMENT OF NAFLD/NASH.ALBIREO ANNOUNCES FDA CLEARANCE OF IND TO COMMENCE PHASE 2 TRIAL OF ELOBIXIBAT FOR THE TREATMENT OF NAFLD/NASH.ALBIREO PHARMA INC - INITIATION OF PHASE 2 CLINICAL TRIAL EXPECTED IN Q2 2019.ALBIREO PHARMA INC - - IBAT INHIBITION HAS POTENTIAL TO IMPACT KEY MARKERS OF NASH -.ALBIREO PHARMA INC - STUDY SHOULD BE INITIATED IN Q2 OF 2019, WITH RESULTS PLANNED FOR MID-2020.  Full Article

Albireo Granted Orphan Drug Designation By FDA For Lead Product Candidate A4250 For Treatment Of Biliary Atresia
Tuesday, 22 Jan 2019 08:30am EST 

Jan 22 (Reuters) - Albireo Pharma Inc ::ALBIREO GRANTED ORPHAN DRUG DESIGNATION BY FDA FOR LEAD PRODUCT CANDIDATE A4250 FOR TREATMENT OF BILIARY ATRESIA.ALBIREO PHARMA INC - PLAN TO EXPAND DEVELOPMENT OF A4250 IN RARE CHOLESTATIC LIVER DISEASES THIS YEAR.  Full Article

FDA Grants Rare Pediatric Disease Designation To A4250
Tuesday, 12 Jun 2018 08:30am EDT 

June 12 (Reuters) - Albireo Pharma Inc ::FDA GRANTS RARE PEDIATRIC DISEASE DESIGNATION TO A4250; ALBIREO ELIGIBLE TO APPLY FOR PRIORITY REVIEW VOUCHER.  Full Article

Albireo Qtrly Net Loss Per Share - Basic And Diluted $0.15
Thursday, 17 May 2018 07:30am EDT 

May 17 (Reuters) - Albireo Pharma Inc ::ALBIREO PROVIDES FIRST QUARTER 2018 BUSINESS UPDATE.ALBIREO PHARMA INC - QTRLY NET LOSS PER SHARE - BASIC AND DILUTED $0.15.  Full Article

Albireo Pharma Inc Files For Non-Timely 10-K ‍​
Monday, 19 Mar 2018 11:40am EDT 

March 19 (Reuters) - Albireo Pharma Inc ::ALBIREO PHARMA INC FILES FOR NON-TIMELY 10-K WITH THE U.S. SEC ‍​.  Full Article

Albireo Reports Fourth Quarter And Year-End 2017 Financial Results
Thursday, 15 Mar 2018 07:30am EDT 

March 15 (Reuters) - Albireo Pharma Inc ::ALBIREO REPORTS FOURTH QUARTER AND YEAR-END 2017 FINANCIAL RESULTS.ALBIREO PHARMA INC - ABOUT $200 MILLION CURRENT CASH BALANCE EXPECTED TO BE SUFFICIENT TO FUND OPERATIONS INTO 2021.ALBIREO PHARMA INC - PHASE 3 PFIC TRIAL OF IBAT INHIBITOR A4250 PLANNED TO INITIATE IN SPRING 2018.  Full Article

Albireo Prices $65.0 Mln Public Offering Of Common Stock
Thursday, 25 Jan 2018 08:45am EST 

Jan 25 (Reuters) - Albireo Pharma Inc ::ALBIREO PRICES $65.0 MILLION PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 1.97 MILLION COMMON SHARES PRICED AT $33.00PER SHARE.  Full Article